654 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Horizon Investment Services LLC

Horizon Investment Services LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 654 shares of the biotechnology company’s stock, valued at approximately $208,000.

Other hedge funds also recently modified their holdings of the company. SG Americas Securities LLC lifted its stake in shares of United Therapeutics by 176.2% during the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after purchasing an additional 4,100 shares during the period. International Assets Investment Management LLC boosted its holdings in shares of United Therapeutics by 13,769.2% during the fourth quarter. International Assets Investment Management LLC now owns 9,015 shares of the biotechnology company’s stock worth $1,982,000 after purchasing an additional 8,950 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of United Therapeutics by 90.3% in the fourth quarter. BNP Paribas Financial Markets now owns 55,481 shares of the biotechnology company’s stock valued at $12,200,000 after purchasing an additional 26,325 shares during the period. Finally, Comerica Bank increased its stake in United Therapeutics by 5.9% in the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the sale, the chief financial officer now owns 2,615 shares in the company, valued at $947,597.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at $947,597.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher Causey sold 2,000 shares of United Therapeutics stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $281.53, for a total value of $563,060.00. Following the sale, the director now directly owns 4,185 shares in the company, valued at $1,178,203.05. The disclosure for this sale can be found here. Insiders sold a total of 119,520 shares of company stock worth $38,572,141 in the last 90 days. 12.50% of the stock is owned by company insiders.

United Therapeutics Stock Down 1.0 %

Shares of United Therapeutics stock opened at $350.01 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The stock has a market cap of $15.53 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 1.31 and a beta of 0.55. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The company has a fifty day moving average price of $333.29 and a 200 day moving average price of $281.92.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the company earned $5.24 EPS. Equities research analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on UTHR shares. JPMorgan Chase & Co. raised their price target on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. Oppenheimer raised their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 28th. Bank of America dropped their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a report on Thursday, July 11th. Finally, TD Cowen upped their price objective on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.